Press release
Regeneron Reports Second Quarter 2024 Financial and Operating Results
Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023Second quarter 2024 Dupixent® global net sales (recorded by Sanofi)
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023Second quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HDSecond quarter 2024 Libtayo® global net sales increased 42% to $297 million versus second quarter 2023Second quarter 2024 GAAP diluted EPS increased 46% to $12.41 and non-GAAP diluted EPS(a) increased 13% to $11.56 versus second quarter 2023; second quarter 2024 includes unfavorable $0.18 impact from acquired IPR&D chargeEuropean Commission approved Dupixent as first-ever biologic therapy for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils TARRYTOWN, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update. \"Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo,\" said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. \"Importantly, Dupixent was granted its first regulatory approval for COPD by the European Commission, with FDA action anticipated in the third quarter, presenting an opportunity to help even more patients around the globe. As always, we remain focused on driving forward our diverse clinical pipeline, progressing late-stage trials for Dupixent in chronic spontaneous urticaria and other dermatologic indications; itepekimab, our IL-33 antibody in COPD; fianlimab, our LAG-3 antibody in metastatic melanoma; and Libtayo in adjuvant cutaneous squamous cell carcinoma. Finally, we were excited to advance several promising earlier-stage programs, including various antibody and GLP-1 combinations for obesity and our gene therapy DB-OTO for genetic hearing loss.\" Financial Highlights ($ in millions, except per share data) Q2 2024 Q2 2023 % ChangeTotal revenues $3,547 $3,158 12%GAAP net income $1,432 $968 48%GAAP net income per share - diluted $12.41 $8.50 46%Non-GAAP net income(a) $1,351 $1,182 14%Non-GAAP net income per share - diluted(a) $11.56 $10.24 13% \"Our second quart...